Coenzyme Q10 and vitamin e deficiency in Friedreich's ataxia: Predictor of efficacy of vitamin e and coenzyme Q10 therapy

European Journal of Neurology

Volumn 15, Issue 12, 2008, Pages 1371-1379

  Cooper, J M ^a   Korlipara, L V P ^a   Hart, P E ^a   Bradley, J L ^a   Schapira, A H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antioxidant therapy; Coenzyme Q10; Friedreich's ataxia

Indexed keywords

ALPHA TOCOPHEROL; BIO E VITAMIN; BIO QUINO Q10; PLACEBO; UBIDECARENONE; UNCLASSIFIED DRUG; ANTIOXIDANT; DRUG DERIVATIVE; MULTIENZYME COMPLEX; UBIQUINONE;

ADOLESCENT; ADULT; ARTICLE; BOWEL FREQUENCY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME THERAPY; FEMALE; FRIEDREICH ATAXIA; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; ALPHA TOCOPHEROL DEFICIENCY; BIOASSAY; BLOOD; DRUG EFFECT; ENERGY METABOLISM; GENETICS; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; SKELETAL MUSCLE; TREATMENT OUTCOME; UPREGULATION;

ADOLESCENT; ADULT; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENDPOINT DETERMINATION; ENERGY METABOLISM; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; MITOCHONDRIA; MUSCLE, STRIATED; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; UBIQUINONE; UP-REGULATION; VITAMIN E; VITAMIN E DEFICIENCY; YOUNG ADULT;

EID: 56049088295     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02318.x     Document Type: Article

References (26)

1. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Human Molecular Genetics 1997 6 : 1771 1780.
2. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981 104 : 589 620.
3. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genetics 1997 17 : 215 217.
4. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Human Molecular Genetics 2000 9 : 275 282.
5. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proceedings of the National Academy of Sciences of the United States of America 1999 96 : 11492 11495.
6. Lodi R, Rajagopalan B, Blamire AM, et al. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study. Cardiovascular Research 2001 52 : 111 119.
7. Schulz JB, Dehmer T, Schols L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000 55 : 1719 1721.
8. Bradley JL, Homayoun S, Hart PE, Schapira AH, Cooper JM. Role of oxidative damage in Friedreich's ataxia. Neurochemical Research 2004 29 : 561 567.
9. Cavadini P, O'Neill HA, Benada O, Isaya G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Human Molecular Genetics 2002 11 : 217 227.
10. Bulteau AL, O'Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004 305 : 242 245.
11. Shan Y, Napoli E, Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Human Molecular Genetics 2007 16 : 929 941.
12. Duby G, Foury F, Ramazzotti A, Herrmann J, Lutz T. A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Human Molecular Genetics 2002 11 : 2635 2643.
13. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Annals of Neurology 2001 49 : 590 596.
14. Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Archieves of Neurology 2005 62 : 621 626.
15. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. Journal of the Neurological Sciences 1997 145 : 205 211.
16. Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. European Heart Journal 2006 27 : 2675 2681.
17. Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001 56 : 849 855.
18. Cooper JM, Bradley JL. Friedreich's ataxia. International Review of Neurobiology 2002 53 : 147 173.
19. Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Movement Disorders 2005 20 : 1585 1591.
20. Ribai P, Pousset F, Tanguy ML, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Archieves of Neurology 2007 64 : 558 564.
21. Rustin P, Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999 354 : 477 479.
22. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003 60 : 1676 1679.
23. Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 2003 60 : 1679 1681.
24. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002 87 : 346 349.
25. Di Prospero NA, Baker A, Jeffries N, Fishbeck KH. Neurological effects of high dose idebenone in patients with Friedreich's ataxia:a randomised, placebo controlled trial. Lancet Neurology 2007 6 : 878 886.
26. Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Human Molecular Genetics 2004 13 : 1017 1024.